A large, multicenter, 3-year extension study assessing efficacy and safety of onabotulinumtoxinA (onabotA) for treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) in patients not adequately managed with an anticholinergic

Trial Profile

A large, multicenter, 3-year extension study assessing efficacy and safety of onabotulinumtoxinA (onabotA) for treatment of urinary incontinence due to neurogenic detrusor overactivity (NDO) in patients not adequately managed with an anticholinergic

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Dec 2015

At a glance

  • Drugs Botulinum toxin (Primary)
  • Indications Urinary incontinence
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top